Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of ametinib in real-world NSCLC use
ChiCTR2600116276Phase 4Completed
- Sponsor
- Beijing Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Hospital. Primary endpoint: Safety evaluation. Started Jan 2026; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600116276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116276.